

OMB APPROVAL
OMB Number: 3235-0060
Expires: April 30, 2009
Estimated average burden hours per response: 38

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): May 25, 2006

Viropro, Inc.
(Exact Name of Registrant as Specified in its Charter)

Nevada	333-06718	13-3124057
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
8515, Place Devonshire, Suite 207 Montreal, Quebec, Canada	H4P 2K1	
(Address of principal executive offices)	(Zip Code)	

Registrant's telephone number, including area code: (514) 731-8776

N/A
(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEC 873 (5-06) **Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

•

ITEM 8.01 – OTHER EVENTS

On May 25, 2006, Viropro Inc. CEO Dr. Jean-Marie Dupuy announced that the Company Board of Directors had authorized the creation of a subsidiary to be named Theravax, Inc.

The newly created division of Viropro is aimed at developing and manufacturing therapeutic vaccines for the treatment of patients suffering from cancer or from chronic infections with viruses such as HIV or hepatitis. The HIV vaccine will be the first product to be developed and marketed. Its development will be carried out with the assistance and involvement of world leaders in the field of HIV/AIDS. Clinical studies are scheduled to start in Canada in 2007. This HIV therapeutic vaccine is expected to be marketed in 2010.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

99.1 – Press release, May 25, 2006

99.2 – Press release, correction, June 1, 2006

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

VIROPRO, INC.

/s/ Jean-Marie Dupuy

Jean-Marie Dupuy
CEO, President, Director

Date: June 19, 2006

Creation of Theravax Inc., a 100 Percent Owned Subsidiary of Viropro Inc., to Develop an HIV Vaccine to Be Tested in Canada

MONTREAL, May 25, 2006 (PRIMEZONE via COMTEX) -- Dr. Jean-Marie Dupuy, President and Chief Executive Officer of Viropro Inc. ("Viropro" or "the company") (OTCBB:VPRO), today announced the creation of Theravax Inc., a division of Viropro, aimed at developing and manufacturing therapeutic vaccines for the treatment of patients suffering from cancer or from chronic infections with viruses such as HIV or hepatitis. The HIV vaccine will be the first product to be developed and marketed. Its development will be carried out with the assistance and involvement of world leaders in the field of HIV/AIDS. Clinical studies are scheduled to start in Canada in 2007. This HIV therapeutic vaccine is expected to be marketed in 2010.

According to a previous phase 2 clinical study, the HIV therapeutic vaccine should allow a significant number of vaccinated AIDS patients to avoid or delay normally required treatment with an anti-HIV tri-therapy, thus avoiding the severe side-effects associated with such treatments.

Using a similar vaccination process, therapeutic vaccines against hepatitis will also be developed. They will then be followed by therapeutic vaccines against various types of cancer.

Therapeutic vaccines are designed to help patients stimulate their own immune system in order to fight diseases. This particular therapeutic vaccine will activate the patients' specific anti-virus or anti-cancer immune system, therefore making a tailor-made vaccine for each patient. "Several academic laboratories have recently obtained interesting clinical results with dendritic cell therapeutic vaccines," stated Dr. Dupuy. "Such data have to be reproduced and the transition from clinical research to pharmaceutical protocols has to meet the requirements of Good Manufacturing Practices. This last step requires industrial expertise," added Dr. Dupuy.

Dr. Dupuy further stated, "In cancer, or in chronic viral infections, dendritic cells are often paralysed and cannot perform their proper function. This technology is designed to have the dendritic cells perform outside the body the function they cannot achieve 'in vivo.'" Dendritic cells can be prepared outside the body ("ex vivo" preparation) in a culture medium mixed with viral or cancer antigens and then be re-injected into the patient in order to stimulate the immune system to attack cancer cells or virus infected cells. On a regular schedule, patients can then receive injections of therapeutic vaccines in order to maintain a strong immune protection.

About Viropro Inc.

Viropro Inc. operates mainly through its subsidiary Viropro International Inc. with its Head Office in Montreal, Canada. Viropro is a company specializing in marketing its know-how and expertise in technology transfer for industrial production of therapeutic proteins. Besides today's announcement, Viropro has concluded other strategic alliances with renowned scientific and business partners, both at the national and international levels. Viropro relies on a business model built to generate short and medium term recurrent revenues while increasing the value of stock for both the company and its shareholders.

For more information on Viropro Inc, please visit our website on www.viropro.com

About Theramune

Theramune, a wholly-owned subsidiary of Viropro Inc., is working at developing and manufacturing autologous dendritic cell-based therapeutic vaccines for treatment of patients with chronic viral infections. The therapeutic vaccine that will be produced in manufacturing units will be made from patients' blood cells loaded with disease-products obtained from the same patients.

Viropro Inc.'s Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbour created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.

This news release was distributed by PrimeZone, www.primezone.com

SOURCE: Viropro, Inc.

By Staff

CONTACT: Viropro Inc.

Daniel Benchetrit, Director: Marketing and Communications
514-731-VPRO (8776) - Extension 225
dbenchetrit@viropro.com

HKDP Communications and public affairs
Jacques C. Gagnon, Senior Consultant
514-395-0375 - Extension 227
jgagnon@hkdp.qc.ca

LMC Communications Inc.
Investor Relations:
514-815-8799
lmccom@videotron.ca

(C) 2006 PRIMEZONE, All rights reserved.

C O R R E C T I O N from source - Viropro Inc. - Theravax/

In c1391 transmitted at 10:53e, May 25, 2006, errors occurred in the second boiler plate. "About Theramune" should have read "About Theravax Inc.", and the first paragraph should have read "Theravax, a wholly-owned subsidiary..." instead of "Theramune, a wholly-owned subsidiary...". Corrected copy follows. Creation of Theravax Inc., to develop a HIV vaccine to be tested in Canada - A 100% owned subsidiary of Viropro Inc. OTC BB- NASDAQ: VPRO

MONTREAL, May 25, 2006 (Canada NewsWire via COMTEX) -- Dr Jean-Marie Dupuy, President and Chief Executive Officer of Viropro Inc., - "Viropro" or 'the company'" (OTC BB - NASDAQ : VPRO) - today announced the creation of Theravax Inc., a division of Viropro, aimed at developing and manufacturing therapeutic vaccines for the treatment of patients suffering from cancer or from chronic infections with viruses such as HIV or hepatitis. The HIV vaccine will be the first product to be developed and marketed. Its development will be carried out with the assistance and involvement of world leaders in the field of HIV/AIDS. Clinical studies are scheduled to start in Canada in 2007. This HIV therapeutic vaccine is expected to be marketed in 2010.

According to a previous phase 2 clinical study, the HIV therapeutic vaccine should allow a significant number of vaccinated AIDS patients to avoid or delay normally required treatment with an anti-HIV tri-therapy, thus avoiding the severe side-effects associated with such treatments.

Using a similar vaccination process, therapeutic vaccines against hepatitis will also be developed. They will then be followed by therapeutic vaccines against various types of cancer.

Therapeutic vaccines are designed to help patients stimulate their own immune system in order to fight diseases. This particular therapeutic vaccine will activate the patients' specific anti-virus or anti-cancer immune system, therefore making a tailor-made vaccine for each patient. "Several academic laboratories have recently obtained interesting clinical results with dendritic cell therapeutic vaccines" stated Dr. Dupuy. "Such data have to be reproduced and the transition from clinical research to pharmaceutical protocols has to meet the requirements of Good Manufacturing Practices. This last step requires industrial expertise" added Dr. Dupuy.

Dr Dupuy further stated "In cancer, or in chronic viral infections, dendritic cells are often paralysed and cannot perform their proper function. This technology is designed to have the dendritic cells perform outside the body the function they cannot achieve "in vivo" Dendritic cells can be prepared outside the body ("ex vivo" preparation) in a culture medium mixed with viral or cancer antigens and then be re-injected into the patient in order to stimulate the immune system to attack cancer cells or virus infected cells. On a regular schedule, patients can then receive injections of therapeutic vaccines in order to maintain a strong immune protection.

About Viropro Inc.

Viropro Inc. operates mainly through its subsidiary Viropro International Inc. with its Head Office in Montreal, Canada. Viropro is a company specializing in marketing its know-how and expertise in technology transfer for industrial production of therapeutic proteins. Besides today's announcement, Viropro has concluded other strategic alliances with renowned scientific and business partners, both at the national and international levels. Viropro relies on a business model built to generate short and medium term recurrent revenues while increasing the value of stock for both the company and its shareholders.

For more information on Viropro Inc, please visit our website on www.viropro.com

About Theravax Inc.

Theravax, a wholly-owned subsidiary of Viropro Inc., is working at developing and manufacturing autologous dendritic cell-based therapeutic vaccines for treatment of patients with chronic viral infections. The therapeutic vaccine that will be produced in manufacturing units will be made from patients' blood cells loaded with disease-products obtained from the same patients.

Viropro Inc.'s Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbour created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.

SOURCE: VIROPRO INC.

SOURCE: THERAVAX

CONTACT:

Direct all inquiries to: Viropro Inc.: Daniel Benchetrit, Director, Marketing & Communications, (514) 731-VPRO (8776), Extension 225, dbenchetrit@viropro.com;

HKDP Communications and public affairs: Jacques C. Gagnon, Senior Consultant, (514) 395-0375, Extension 227, jgagnon@hkdp.qc.ca;

Investor Relations: LMC Communications Inc., (514) 815-8799, lmccom@videotron.ca

Copyright (C) 2006 CNW Group. All rights reserved.